Background: Congenital adrenal hyperplasia (CAH), the most common cause of ambiguous genitalia of the newborn, requires rapid assessment by a multidisciplinary team including a neonatologist, paediatric endocrinologist, paediatric urologist and geneticist. There is also a role for the clinical psychologist with psychosexual counselling experience as families cope with disorders of sex development. This brief review summarises the continuum of disorders that are manifested in patients with CAH according to age and sex, with emphasis on the lifetime nature of the issues that accompany this disorder and on the long-lasting ramifications of pediatric management decisions for both males and females. Conclusions: There are many management aspects of caring for patients with CAH that clearly fall into the purview of paediatricians or adult-care physicians. There are also areas where responsibilities overlap and require several professionals providing coordinated care.

1.
Hughes IA: Congenital adrenal hyperplasia: 21-hydroxylase deficiency in the newborn and during infancy. Semin Reprod Med 2002;20:229–242.
2.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP: Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635–1639.
3.
Dörr HG: Is there a need to optimize growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH)? Horm Res 2007;in press
4.
Minto CL, Liao LM, Woodhouse CR, Ransley PG, Creighton SM: The effect of clitoral surgery on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a cross-sectional study. Lancet 2003;61:1252–1257.
5.
Crouch NS, Minto CL, Laio LM, Woodhouse CR, Creighton SM: Genital sensation after feminizing genitoplasty for congenital adrenal hyperplasia: a pilot study. BJU Int 2004;93:135–138.
6.
Clayton PE, Miller WL, Oberfield SE, Ritzén EM, Sippell WG, Speiser PW, ESPE/LWPES CAH Working Group: Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002;58:188–195.
7.
Joint LWPES/ESPE CAH Working Group: Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87:4048–4053.
8.
Houk CP, Hughes IA, Ahmed SF, Lee PA, Writing Committee for the International Intersex Consensus Conference Participants: Summary of consensus statement on intersex disorders and their management. International Consensus Conference. Pediatrics 2006;118:753–757.
9.
Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group: Consensus statement on management of intersex disorders. Arch Dis Child 2006;91:554–563.
10.
Prader A: Der Genitalbefund beim Pseudohermaphroditismus femininus des kongenitalen androgenitalen Syndroms. Helv Paediatr Acta 1954;9:231–248.
11.
Greenberg J: International legal developments protecting the autonomy rights of sexual minorities; in Sytsma SE (ed): Ethics and Intersex. Netherlands, Springer, 2006, pp 87–101.
12.
Crouch NS, Creighton SM: Long-term functional outcomes of female genital reconstruction in childhood. BJU Int 2007;100:403–407.
13.
Lee PA, Witchel SF: 46,XX patients with congenital adrenal hyperplasia: initial assignment as male, reassigned female. J Pediatr Endocrinol Metab 2005;18:125–132.
14.
Nordenström A, Servin A, Bohlin G, Larsson A, Wedell A: Sex-typed toy play behavior correlates with the degree of prenatal androgen exposure assessed by CYP21 genotype in girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2002;87:5119–5124.
15.
Hall CM, Jones JA, Meyer-Bahlburg HF, Dolezal C, Coleman M, Foster P, Price DA, Clayton PE: Behavioral and physical masculinization are related to genotype in girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:419–424.
16.
Martin CL, Ruble DN, Szkrybalo J: Cognitive theories of early gender development. Psychol Bull 2002;128:903–933.
17.
Ozbey H, Darendeliler F, Kayserili H, Korkmazlar U, Salman T: Gender assignment in female congenital adrenal hyperplasia: a difficult experience. BJU Int 2004;94:388–391.
18.
Dessens AB, Slijper FM, Drop SL: Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia. Arch Sex Behav 2005;334:389–397.
19.
Ogilvie CM, Crouch NS, Rumsby G, Creighton SM, Liao L, Conway GS: Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol 2006;64:2–11.
20.
Gastaud F, Bouvattier C, Duranteau L, Brauner R, Thibaud E, Kutten F, Bougnères P: Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007;92:1391–1396.
21.
Premawardhana LD, Hughes IA, Read GF, Scanlon MF: Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 2007;46:327–332.
22.
Hoepffner W, Schulze E, Bennek J, Keller E, Willgerodt H: Pregnancies in patients with congenital adrenal hyperplasia with complete or almost complete impairment of 21-hydroxylase activity. Fertil Steril 2004;81:1314–1321.
23.
Stikkelbroeck NM, Suliman HM, Otten BJ, Hermus AR, Blickman JG, Jager GJ: Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. Eur Radiol 2003;13:1597–1603.
24.
Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA: Testicular adrenal rest tumours in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 2007;June 1 Epub ahead of print.
25.
Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Hermus AR: Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007;May 19 Epub ahead of print.
26.
Stikkelbroeck NM, Hermus AR, Suliman HM, Jager GJ, Otten BJ: Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. J Pediatr Endocrinol Metab 2004;17:645–653.
27.
Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP: Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 2002;87:2114–2120.
28.
Hughes IA: Congenital adrenal hyperplasia – a continuum of disorders. Lancet 1998;352:752–754.
29.
Murtaza L, Sibert JR, Hughes I, Balfour IC: Congenital adrenal hyperplasia – a clinical and genetic survey. Are we detecting male salt-losers? Arch Dis Child 1980;55:622–625.
30.
Nordenström A, Ahmed S, Jones J, Coleman M, Price DA, Clayton PE, Hall CM: Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res 2005;63:22–28.
31.
Grosse SD, Van Vliet G: How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007;67:284–291.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.